CRANBURY, N.J.--(BUSINESS WIRE)--OncLive®, the leading digital provider of resources and information for oncology professionals, announces its latest webinar, “Androgen Deprivation Therapy in Prostate Cancer and Cardiovascular Risk,” on May 1 at 2 p.m. (ET).
“This webinar offers a perfect opportunity for oncology professionals to hear multidisciplinary experts discuss the advances in hormone therapy, such as androgen deprivation therapy (ADT),” said Michael J. Hennessy Jr., president of MJH Associates, parent company of OncLive®. “We look forward to hosting this educational webinar to help clinicians transform lives of patients.”
Distinguished presenters from Memorial Sloan Kettering Cancer Center in New York, New York, for the webinar are as follows:
- Dipti Gupta, M.D., M.P.H., clinical cardiologist
- Susan F. Slovin, M.D., Ph.D., medical oncologist
“This format helps educate the audience in an interactive setup,” said Robert Goldsmith, vice-president of OncLive®. “Together with our featured speakers, we will explore emerging therapies and address audience questions in real time.”
The webinar will discuss topics including cardioprotective role of androgens, metabolic changes associated with ADT and management algorithm for patients on ADT. The featured presenters will also address questions submitted by the attendees regarding ADT and cardiovascular risks during the webinar.
To register for the webinar, visit http://www.onclive.com/live-broadcast/androgen-deprivation-therapy.
About OncLive®
A digital platform of resources for practicing oncologists, OncLive® offers oncology professionals information they can use to help provide the best patient care. OncLive.com is the official website for MJH Associates’ Oncology Specialty Group, which publishes OncologyLive®, Oncology Nursing News® and more. MJH Associates is a full-service health care communications company offering education, research, and medical media, including curetoday.com and CURE® magazine, the largest U.S. consumer publication focused entirely on cancer. Combining science and humanity to make cancer understandable, CURE® reaches patients, cancer centers and advocacy groups.
